Boston Scientific Has Agreed To Acquire Relievant Medsystems For An Upfront Cash Payment Of $850M And Undisclosed Additional Contingent Payments Based On Sales Performance Over The Next Three Years
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has agreed to acquire Relievant Medsystems for an upfront cash payment of $850M and undisclosed additional contingent payments based on sales performance over the next three years.
September 19, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Boston Scientific's acquisition of Relievant Medsystems could potentially enhance its product portfolio and market presence, but also involves significant upfront cash outlay.
The acquisition could potentially enhance Boston Scientific's product portfolio and market presence, which may positively impact its stock in the long term. However, the significant upfront cash outlay of $850M could put a strain on its financial resources in the short term, potentially leading to a neutral or negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100